Tempus AI Wins $200 Million AstraZeneca Commitment — Early Termination Still Requires A Shortfall Payment
The five-year renewal sets a $32 million annual minimum for fees across Tempus's products and services.
Tempus AI, which links diagnostic testing to patients' clinical data, signed a five-year renewal Monday securing a $200 million commitment from AstraZeneca. Tempus said in Wednesday's SEC filing that AstraZeneca would owe any remaining shortfall if it ended the services agreement for convenience.
A Spending Floor, Plus An Exit Payment
AstraZeneca's commitment covers fees paid or owed under the services agreement and other agreements involving the companies and their affiliates. It applies to Tempus's current products and services as well as those added during the renewal period.
The agreement sets annual target spending of $40 million and requires at least $32 million in fees each calendar year. Those figures serve different purposes: one is the annual spending target, the other the yearly minimum AstraZeneca agreed to meet.
AstraZeneca keeps the option to end the services agreement for convenience at any time. Exercising that right would make it liable for the unmet portion of the $200 million commitment as of the termination's effective date.
Labs And Data Under One Relationship
Tempus operates both a diagnostics business and a data-and-applications business. Its diagnostics offerings include genomic sequencing and pathology tests for healthcare providers, life sciences companies and researchers, mainly focused on making cancer testing more personal.
Its data-and-applications products—Insights, Trials, Next and Algos—offer de-identified data licensing, analytics, clinical trial support and algorithm-based diagnostics to pharmaceutical and biotechnology companies.
Tempus operates five testing laboratories and has about 700 direct data connections across roughly 5,000 hospitals. Its provider network covers more than 55% of U.S. oncologists. As of December 31, 2025, its database contained more than 8.6 million de-identified patient records.
The Renewal Can Run Into 2032
The companies began their services relationship under an agreement dated November 17, 2021, which they had amended before Monday's renewal. AstraZeneca's strategic collaborator benefits will continue under the renewed arrangement.
The amendment takes effect January 1, 2027, and extends the agreement through December 31, 2031. If the aggregate commitment remains unmet at that point, the renewal period will extend through December 31, 2032, to address the shortfall.
Sources
- 8-K Filing — Tempus AI, Inc. (TEM) — SEC EDGAR